Mediar Therapeutics

Mediar Therapeutics is a biotechnology company in the exploration stage, developing treatments to halt or even reverse fibrosis. Our platform and pipeline are based on an emerging class of novel targets, where fibrotic mediators play a key role in regulating myofibroblasts. These cells are drivers of the pathophysiology of diseases such as cirrhosis, which leads to long-term organ damage.